Xtalks is proud to announce the release of the sixth issue of Xtalks Clinical Edge™, featuring conversations that highlight how science and leadership are driving meaningful change in clinical research.
Since its inception, Xtalks Clinical Edge has become a trusted digital magazine for thought leadership, connecting the voices driving innovation across clinical research, including global pharma and biotech leaders, digital health pioneers, regulators and patient advocates.
Each issue brings together fresh perspectives and real-world insights on the strategies, technologies and collaborations that are shaping how trials are designed, conducted and delivered.
With a readership of more than 86,000 engaged clinical trial professionals, the magazine continues to highlight the people and ideas transforming discovery into meaningful patient impact.
Highlights from Xtalks Clinical Edge Issue 6
The sixth issue of Xtalks Clinical Edge brings together 18 in-depth conversations with organizations at the forefront of advancing what’s possible in clinical research today.
Spanning neuroscience, oncology, cardiology, dermatology, ophthalmology and rare diseases, this issue captures how leaders across the clinical research ecosystem are redefining innovation through science, strategy and collaboration.
Cardiovascular Research and Real-World Evidence
In cardiovascular research, Bristol Myers Squibb shares how global real-world evidence (RWE) programs are transforming the understanding of hypertrophic cardiomyopathy, enabling researchers to translate complex data into actionable insights for improving patient outcomes. Complementing this perspective, Medtronic explores a groundbreaking global trial focused on personalized pacing for heart failure, illustrating how device innovation and data integration are advancing precision care and the future of cardiac medicine.
Oncology and Immunotherapy Innovation
Innovation in oncology and immunotherapy continues to accelerate. Boehringer Ingelheim discusses how biomarker testing and precision oncology are reshaping treatment paradigms in non-small cell lung cancer (NSCLC), enabling more tailored and effective therapies. Pyxis Oncology builds on this conversation with insights into the evolution of antibody-drug conjugates (ADCs), revealing how advances in linker and payload design are expanding the therapeutic window for patients. Meanwhile, CNS Pharmaceuticals outlines new strategies to overcome the blood-brain barrier in glioblastoma, and Actuate Therapeutics demonstrates how data-driven trial design can help extend survival in pancreatic cancer, one of oncology’s most formidable challenges.
Precision Medicine and Neuroscience
Precision medicine also takes center stage in this issue. Cerevance shows how combining human brain data with AI is ushering in a new era of precision neurology for Parkinson’s disease, bridging molecular insight with clinical application. Similarly, Faron Pharmaceuticals emphasizes the importance of genomics and tumor immune microenvironment research in reshaping the design and endpoints of trials in myelodysplastic syndrome, pointing to a future where patient-specific data drive smarter, more adaptive clinical strategies.
Cell Therapy Innovation
The magazine also explores the expanding frontier of cell therapy, where new modalities are redefining therapeutic potential. FibroBiologics introduces fibroblast-based therapeutics as a promising new class of treatments with applications spanning immune modulation, wound healing and longevity. Building on this momentum, Lineage Cell Therapeutics reflects on the growing maturity of regenerative medicine and underscores why in-house manufacturing capabilities are critical to scaling allogeneic cell therapies globally.
Data, Equity and Collaboration
Several features in this issue highlight how data, equity and collaboration are becoming cornerstones of modern clinical research. Chiesi Group explores how AI, RWE and digital health technologies are accelerating progress in rare disease studies, creating faster and more inclusive pathways to discovery. Takeda expands on this theme by sharing how ethical and patient-centered trial design is shaping the future of rare disease development. Lexicon Pharmaceuticals examines the intersection of regulatory pragmatism and patient advocacy, while UCB offers a leadership perspective on how authenticity and inclusion are driving progress in immunology and enhancing diversity across clinical programs.
Dermatology, Ophthalmology and Emerging Biotech Hubs
Rounding out the issue, Xtalks Clinical Edge turns its attention to dermatology, ophthalmology and the broader innovation ecosystem. Galderma demonstrates how patient-reported outcomes (PROs) and long-term real-world data (RWD) are redefining success metrics in dermatology, aligning clinical endpoints more closely with quality-of-life improvements. In ophthalmology, Iolyx Therapeutics showcases how pragmatic, real-world trial designs are transforming approaches to dry eye disease, emphasizing accessibility and real-world applicability. Finally, the issue spotlights the infrastructures fueling tomorrow’s breakthroughs: the Chicago Biomedical Consortium reveals how the Midwest is emerging as a powerhouse for biotech translation and talent retention, while Ratio Therapeutics provides a behind-the-scenes look at the science and logistics driving next-generation radiopharmaceuticals.
Together, these stories offer a panoramic view of an industry in motion, one that continues to evolve through data, technology and an firm commitment to improving patient outcomes.
Why You Should Be Featured in Xtalks Clinical Edge
Xtalks Clinical Edge is more than a publication. It’s a platform for leaders shaping the next generation of clinical research.
If your organization provides the technologies, services or expertise that enable innovation in clinical trials, Xtalks Clinical Edge offers a high-impact opportunity to showcase your leadership to a global audience of industry decision-makers.
Through editorial features, executive Q&As and thought leadership articles, we collaborate with sponsors, CROs, technology providers, data analytics firms and patient engagement specialists to tell meaningful stories that resonate with the clinical research community.
By being featured, your organization can:
- Elevate its voice as a thought leader among peers in pharma, biotech and medtech
- Highlight real-world impact through expert insights, data-driven results and case studies
- Reach global decision-makers across the clinical trial ecosystem through Xtalks’ audience of over 86,000 clinical research professionals
Whether you’re advancing trial design, inclusion, digital endpoints or decentralized solutions, Xtalks Clinical Edge provides a platform to position your company at the forefront of progress.
To explore partnership or feature opportunities, connect with:
Gabriela Bravo, Global Director, Value Added Services, Xtalks
Email: [email protected]
Phone: +1 289-306-0359
Join or login to leave a comment
JOIN LOGIN